AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology.
The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products.
The Salix segment provides gastroenterology products in the United States.
The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East.
The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally.
The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.
Country | CA |
IPO Date | Mar 29, 1994 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 20,270 |
CEO | Thomas J. Appio |
Contact Details
Address: 2150 St. ElzEar Boulevard West Laval, QC CA | |
Website | https://www.bauschhealth.com |
Stock Details
Ticker Symbol | BHC |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000885590 |
CUSIP Number | 071734107 |
ISIN Number | CA0717341071 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Thomas J. Appio | Chief Executive Officer & Director |
Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer |
Mirza Dautbegovic | Executive Vice President & Chief Operating Officer |
Aimee J. Lenar | Executive Vice President of US Pharma |
Cees Heiman | Senior Vice President of Europe & Canada |
Donald Pearl | Senior Vice President of Ortho Dermatologics |
Garen Sarafian | Vice President & Head of Investor Relations |
Jiny Kim M.B.A. | Senior Vice President of Solta Medical |
Kathleen Fitzpatrick | Executive Vice President and Chief HR & Communications Officer |
Seana Carson | Executive Vice President & General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 02, 2025 | 4 | Filing |
Jan 02, 2025 | 4 | Filing |
Jan 02, 2025 | 4 | Filing |
Dec 03, 2024 | 4 | Filing |
Nov 01, 2024 | 8-K | Current Report |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 30, 2024 | 8-K | Current Report |
Oct 01, 2024 | 4 | Filing |
Oct 01, 2024 | 4 | Filing |
Oct 01, 2024 | 4 | Filing |